Antigen presenting cell response to polysaccharide A is characterized by the generation of anti-inflammatory macrophages.
RNAseq
immune regulation
macrophage
polysaccharide
transcriptomics
Journal
Glycobiology
ISSN: 1460-2423
Titre abrégé: Glycobiology
Pays: England
ID NLM: 9104124
Informations de publication
Date de publication:
19 03 2022
19 03 2022
Historique:
received:
05
08
2021
revised:
01
10
2021
accepted:
16
10
2021
pubmed:
24
12
2021
medline:
15
4
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
Polysaccharide A (PSA) is the immunodominant capsular carbohydrate from the gram negative commensal microbe Bacteroides fragilis that has shown remarkable potency in ameliorating many rodent models of inflammatory disease by eliciting downstream suppressive CD4+ T cells. PSA is composed of a zwitterionic repeating unit that allows it to be processed by antigen presenting cells (APCs) and presented by MHCII in a glycosylation-dependent manner. While previous work has uncovered much about the interactions between MHCII and PSA, as well as the downstream T cell response, little is known about how PSA affects the phenotype of MHCII+ APCs, including macrophages. Here, we utilized an unbiased systems approach consisting of RNAseq transcriptomics, high-throughput flow cytometry, Luminex analysis and targeted validation experiments to characterize the impact of PSA-mediated stimulation of splenic MHCII+ cells. The data revealed that PSA potently elicited the upregulation of an alternatively activated M2 macrophage transcriptomic and cell surface signature. Cell-type-specific validation experiments further demonstrated that PSA-exposed bone marrow-derived macrophages (BMDMs) induced cell surface and intracellular markers associated with M2 macrophages compared with conventional peptide ovalbumin (ova)-exposed BMDMs. In contrast to macrophages, we also found that CD11c+ dendritic cells (DCs) upregulated the pro-T cell activation costimulatory molecule CD86 following PSA stimulation. Consistent with the divergent BMDM and DC changes, PSA-exposed DCs elicited an antigen-experienced T cell phenotype in co-cultures, whereas macrophages did not. These findings collectively demonstrate that the PSA-induced immune response is characterized by both T cell stimulation via presentation by DCs, and a previously unrecognized anti-inflammatory polarization of macrophages.
Identifiants
pubmed: 34939104
pii: 6433003
doi: 10.1093/glycob/cwab111
pmc: PMC8934142
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Polysaccharides
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136-147Subventions
Organisme : NCI NIH HHS
ID : P30 CA043703
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI154899
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI089474
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Glycobiology. 2018 Dec 1;28(1):50-58
pubmed: 29087497
J Immunol. 1998 May 15;160(10):5000-6
pubmed: 9590249
Glycobiology. 2015 Apr;25(4):368-75
pubmed: 25347992
Clin Exp Immunol. 2019 Jan;195(1):74-85
pubmed: 29920643
Cell Metab. 2019 Nov 5;30(5):917-936.e10
pubmed: 31447322
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1135-44
pubmed: 23640482
Mucosal Immunol. 2010 Sep;3(5):487-95
pubmed: 20531465
Elife. 2021 Feb 22;10:
pubmed: 33617447
Autoimmun Rev. 2016 Sep;15(9):859-69
pubmed: 27392501
Cell. 2004 May 28;117(5):677-87
pubmed: 15163414
J Immunol. 2015 Jan 1;194(1):177-86
pubmed: 25472994
J Immunol. 1986 Jul 1;137(1):341-6
pubmed: 3486915
J Immunol. 1999 Jul 15;163(2):893-7
pubmed: 10395684
Front Immunol. 2020 Oct 26;11:556813
pubmed: 33193325
J Innate Immun. 2013;5(4):389-400
pubmed: 23571507
J Biol Chem. 2015 Feb 20;290(8):5007-5014
pubmed: 25540199
J Immunol. 2010 Oct 1;185(7):4101-8
pubmed: 20817872
Front Immunol. 2021 May 05;12:662807
pubmed: 34025663
Nat Commun. 2017 Dec 21;8(1):2239
pubmed: 29269852
Diabetes. 2019 Oct;68(10):1975-1989
pubmed: 31311801
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12204-9
pubmed: 20566854
PLoS One. 2019 May 23;14(5):e0216893
pubmed: 31120919
Methods Mol Biol. 2019;1954:25-35
pubmed: 30864121
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2008 May 29;453(7195):620-5
pubmed: 18509436
J Clin Invest. 1995 Dec;96(6):2727-31
pubmed: 8675640
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Cell Microbiol. 2005 Oct;7(10):1398-403
pubmed: 16153240
J Vis Exp. 2016 Apr 14;(110):
pubmed: 27168390
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5336-41
pubmed: 12697896
Infect Immun. 1978 Mar;19(3):1083-7
pubmed: 640723
BMC Biol. 2017 Jun 29;15(1):53
pubmed: 28662662
Nat Commun. 2019 Sep 25;10(1):4353
pubmed: 31554795
Front Biosci (Landmark Ed). 2010 Jan 01;15(1):25-34
pubmed: 20036803
Nat Commun. 2014 Jul 21;5:4432
pubmed: 25043484
J Leukoc Biol. 2010 Oct;88(4):687-97
pubmed: 20628063
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
mBio. 2014 Sep 30;5(5):e01548-14
pubmed: 25271284
Clin Microbiol Rev. 2007 Oct;20(4):593-621
pubmed: 17934076
Front Immunol. 2019 May 24;10:1084
pubmed: 31178859